JPH0431674B2 - - Google Patents
Info
- Publication number
- JPH0431674B2 JPH0431674B2 JP59134556A JP13455684A JPH0431674B2 JP H0431674 B2 JPH0431674 B2 JP H0431674B2 JP 59134556 A JP59134556 A JP 59134556A JP 13455684 A JP13455684 A JP 13455684A JP H0431674 B2 JPH0431674 B2 JP H0431674B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- monoclonal antibody
- cancer cells
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 76
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 28
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 15
- 201000007270 liver cancer Diseases 0.000 claims description 14
- 208000014018 liver neoplasm Diseases 0.000 claims description 14
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 238000011580 nude mouse model Methods 0.000 claims description 5
- 241000699660 Mus musculus Species 0.000 claims description 4
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 210000004989 spleen cell Anatomy 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 201000009030 Carcinoma Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 20
- 239000002609 medium Substances 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 210000000628 antibody-producing cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 3
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 3
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59134556A JPS6115897A (ja) | 1984-06-29 | 1984-06-29 | ヒト肝癌細胞を特異的に認識するモノクロ−ナル抗体 |
| US06/749,564 US4820641A (en) | 1984-06-29 | 1985-06-27 | Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells |
| DE8585108073T DE3580524D1 (de) | 1984-06-29 | 1985-06-28 | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. |
| AT85108073T ATE58397T1 (de) | 1984-06-29 | 1985-06-28 | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. |
| EP85108073A EP0166458B1 (en) | 1984-06-29 | 1985-06-28 | Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59134556A JPS6115897A (ja) | 1984-06-29 | 1984-06-29 | ヒト肝癌細胞を特異的に認識するモノクロ−ナル抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6115897A JPS6115897A (ja) | 1986-01-23 |
| JPH0431674B2 true JPH0431674B2 (enExample) | 1992-05-27 |
Family
ID=15131083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59134556A Granted JPS6115897A (ja) | 1984-06-29 | 1984-06-29 | ヒト肝癌細胞を特異的に認識するモノクロ−ナル抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4820641A (enExample) |
| EP (1) | EP0166458B1 (enExample) |
| JP (1) | JPS6115897A (enExample) |
| AT (1) | ATE58397T1 (enExample) |
| DE (1) | DE3580524D1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6357596A (ja) * | 1986-08-29 | 1988-03-12 | Nisshin Flour Milling Co Ltd | モノクロ−ナル抗体、その製法およびそれからなる肝疾患診断剤 |
| JPH0798000B2 (ja) * | 1987-05-23 | 1995-10-25 | 萩原 義秀 | ガン関連抗原特異的ヒト免疫グロブリン |
| JPH0829078B2 (ja) * | 1991-11-25 | 1996-03-27 | 萩原 義秀 | ガン関連抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ |
| JPH05268988A (ja) * | 1992-03-05 | 1993-10-19 | Hagiwara Yoshihide | ガン関連抗原特異的ヒト免疫グロブリン |
| US5760000A (en) * | 1994-05-13 | 1998-06-02 | University Technologies International,Inc. | Inhibition of liver cancer by the use of GnRH and GnRH analogs |
| US7491801B2 (en) * | 2000-09-01 | 2009-02-17 | International Bioimmune Systems, Inc. | Identification and development of specific monoclonal antibodies to squamous cell carcinoma |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579827A (en) * | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
-
1984
- 1984-06-29 JP JP59134556A patent/JPS6115897A/ja active Granted
-
1985
- 1985-06-27 US US06/749,564 patent/US4820641A/en not_active Expired - Fee Related
- 1985-06-28 EP EP85108073A patent/EP0166458B1/en not_active Expired - Lifetime
- 1985-06-28 DE DE8585108073T patent/DE3580524D1/de not_active Expired - Lifetime
- 1985-06-28 AT AT85108073T patent/ATE58397T1/de active
Non-Patent Citations (1)
| Title |
|---|
| HEPATOLOGY=1982 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3580524D1 (de) | 1990-12-20 |
| EP0166458A3 (en) | 1988-05-18 |
| JPS6115897A (ja) | 1986-01-23 |
| US4820641A (en) | 1989-04-11 |
| EP0166458B1 (en) | 1990-11-14 |
| EP0166458A2 (en) | 1986-01-02 |
| ATE58397T1 (de) | 1990-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3490443B2 (ja) | 血管形成阻害性抗体 | |
| JP2001521520A (ja) | 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト | |
| HU190908B (en) | Process for preparing humane-humane hybridomes and - by means thereof - monoclonal antibodies | |
| JPH03502885A (ja) | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 | |
| JP7020656B2 (ja) | 組織因子を標的とする抗体、その調製方法及びその使用 | |
| JPH05213775A (ja) | Ｂｆａ抗体 | |
| CA1340350C (en) | Monoclonal antibody to the 75 kd subunit of the human interleukin-2 receptor and use thereof | |
| JPS595121A (ja) | モノクロナル抗体 | |
| JPH0431674B2 (enExample) | ||
| JPH05503098A (ja) | セプシスの処理のためのサイトカイン抗体 | |
| JPH05501351A (ja) | プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用 | |
| JPH0246297A (ja) | モノクローナル抗体、抗体産生ハイブリドーマおよび抗体の製造法 | |
| CN114456267A (zh) | 一种抗cd73人源化单克隆抗体及其应用 | |
| JPH05170667A (ja) | バイスペシフィック抗体 | |
| WO1989009831A1 (en) | Lak cell cytotoxin | |
| JPH02196799A (ja) | 抗ヒト癌蛋白複合体 | |
| JPH0430278B2 (enExample) | ||
| JPH04211612A (ja) | モノクローナル抗体の新用途 | |
| JP2544146B2 (ja) | 上咽頭癌治療剤 | |
| JPH02219594A (ja) | 肺癌に対するモノクローナル抗体および細胞表面抗原 | |
| JP2845568B2 (ja) | モノクローナル抗体 | |
| JPH0530991A (ja) | 抗ガングリオシドモノクローナル抗体 | |
| WO2000000591A1 (en) | Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cells and hybridomas for their production | |
| JPH0217160B2 (enExample) | ||
| JPH0320239B2 (enExample) |